Wednesday - July 29, 2026
Dana-Farber Phase 1 Study Explores Toxicity Reduction in Combination of Trastuzumab Deruxtecan and Olaparib in Advanced HER2-Expressing Malignancies
April 19, 2026
BOSTON, Massachusetts, April 19 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:

* * *

Dana-Farber Phase 1 Study Explores Toxicity Reduction in Combination of Trastuzumab Deruxtecan and Olaparib in Advanced HER2-Expressing Malignancies

*

A phase 1 study aiming to test tolerability of combination therapy with trastuzumab deruxtecan and olaparib in Human Epidermal Growth Factor Receptor 2 (HER2)-expre . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Click here for more information about our products